Xilio Therapeutics (NASDAQ:XLO) Shares Up 0.9% – Here’s Why

Xilio Therapeutics, Inc. (NASDAQ:XLO)’s share price rose 0.9% during mid-day trading on Monday . The company traded as high as $0.5533 and last traded at $0.5458. Approximately 237,294 shares were traded during trading, a decline of 49% from the average daily volume of 461,846 shares. The stock had previously closed at $0.5409.

Analyst Ratings Changes

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Xilio Therapeutics in a research note on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $2.00.

Xilio Therapeutics Price Performance

The stock’s 50 day moving average is $0.65 and its two-hundred day moving average is $0.71. The stock has a market capitalization of $36.86 million, a PE ratio of -0.84 and a beta of -0.06.

Xilio Therapeutics (NASDAQ:XLO) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.03) EPS for the quarter, meeting analysts’ consensus estimates of ($0.03). Xilio Therapeutics had a negative net margin of 183.90% and a negative return on equity of 679.66%. The company had revenue of $19.07 million for the quarter, compared to the consensus estimate of $18.64 million. On average, equities analysts predict that Xilio Therapeutics, Inc. will post -1.14 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Xilio Therapeutics stock. Squarepoint Ops LLC increased its holdings in shares of Xilio Therapeutics, Inc. (NASDAQ:XLO) by 39.6% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 328,794 shares of the company’s stock after purchasing an additional 93,338 shares during the quarter. Squarepoint Ops LLC owned approximately 0.63% of Xilio Therapeutics worth $277,000 at the end of the most recent quarter. 54.29% of the stock is currently owned by institutional investors and hedge funds.

Xilio Therapeutics Company Profile

Xilio Therapeutics is a clinical‐stage biotechnology company focused on the discovery and development of tumor‐targeted cytokine therapeutics for the treatment of cancer. The company leverages a proprietary platform to design pro‐drug versions of potent immune‐modulating cytokines, enabling local activation of immune responses within the tumor microenvironment while limiting systemic exposure and toxicity.

The company’s lead programs utilize engineered interleukin‐12 (IL‐12) and interleukin‐2 (IL‐2) molecules fused to tumor‐binding antibodies or peptide ligands.